Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 20Carcinoma, Hepatocellular 8Stomach Neoplasms 6Multiple Myeloma 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Melanoma 3Febrile Neutropenia 3Waldenstrom Macroglobulinemia 2Venous Thromboembolism 2Skin Neoplasms 2Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 2Obesity 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hepatitis B 2Hematologic Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Anemia 2

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × ALK-positive Advanced NSCLC × Clear all
NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study

Fujian Medical University Union Hospital

Phase 4 Not yet recruiting
30 enrolled
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡